24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:04
“AI tools will not replace doctors, but they will save us work”
13:43
Maya Kadouri appointed Chief Strategy Officer at investment AI company BridgeWise
13:33
Two Israeli startups raised half a billion dollars. Their exits reveal the cost of the funding boom
13:10
Full list of Israeli high-tech funding rounds in 2026
More stories
Buzz
Most popular
Daily
Weekly
1
Israel searches for technology that could find soldiers and pilots who cannot call for help
2
Another 10 U.S. tankers are headed to Israel's Ben Gurion as airport delays mount
3
ServiceNow continues layoffs as it restructures around AI
4
After IAI and Rafael, secretive missile engine maker Tomer moves toward an IPO
5
Israel's Iron Dome and Arrow makers unlikely to reach the IPO market before 2027 as Tomer joins the queue
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026